α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation

Discovery and optimization of α-mangostin derivatives as novel PDE4 inhibitors for the treatment of vascular dementia

(2020) Jinhao Liang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Canthin-6-One Accelerates Alpha-Synuclein Degradation by Enhancing UPS Activity: Drug Target Identification by CRISPR-Cas9 Whole Genome-Wide Screening Technology

(2019) Ning-Ning Yuan et al.   Frontiers in Pharmacology

Natural alkaloid harmine promotes degradation of Alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation

(2019) Cui-Zan Cai et al.   PHYTOMEDICINE

PDE1 inhibition facilitates proteasomal degradation of misfolded proteins and protects against cardiac proteinopathy

(2019) Hanming Zhang et al.   Science Advances

Amyloid assembly and disassembly

(2018) Edward Chuang et al.   JOURNAL OF CELL SCIENCE

Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing

(2018) Barry Boland et al.   NATURE REVIEWS DRUG DISCOVERY

The Molecular Basis for Specificity at the Level of the Protein Kinase a Catalytic Subunit

(2018) Kristoffer Søberg et al.   Frontiers in Endocrinology

Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) E. Ray Dorsey et al.   LANCET NEUROLOGY

Therapeutic approaches to target alpha-synuclein pathology

(2017) Patrik Brundin et al.   EXPERIMENTAL NEUROLOGY

Defects in trafficking bridge Parkinson's disease pathology and genetics

(2016) Asa Abeliovich et al.   NATURE

Phenotypic spectrum of alpha-synuclein mutations: New insights from patients and cellular models

(2016) Simona Petrucci et al.   PARKINSONISM & RELATED DISORDERS

Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies

(2015) Anne Stuendl et al.   BRAIN

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations

(2015) Benjamin Dehay et al.   LANCET NEUROLOGY

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling

(2015) Natura Myeku et al.   NATURE MEDICINE

cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins

(2015) Sudarsanareddy Lokireddy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A dynamic interface between ubiquitylation and cAMP signaling

(2015) Laura Rinaldi et al.   Frontiers in Pharmacology

The role of phosphodiesterases in hippocampal synaptic plasticity

(2013) Thomas M. Sanderson et al.   NEUROPHARMACOLOGY

Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy

(2012) Jia-Hong Lu et al.   Autophagy

Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice

(2012) Kelvin C. Luk et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity

(2010) Karin M. Danzer et al.   FASEB JOURNAL

Are synucleinopathies prion-like disorders?

(2010) Elodie Angot et al.   LANCET NEUROLOGY

Pre-fibrillar α-synuclein variants with impaired β-structure increase neurotoxicity in Parkinson's disease models

(2009) Damla Pinar Karpinar et al.   EMBO JOURNAL